Literature DB >> 26984415

Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

Sven-Petter Haugvik1,2,3, Daniel Kaemmerer4, Sebastien Gaujoux5, Knut Jørgen Labori6, Caroline Sophie Verbeke7,8, Ivar Prydz Gladhaug6,7.   

Abstract

Pancreatic neuroendocrine neoplasms (PNENs) are rare, accounting for less than 5% of all pancreatic tumors. High-grade pancreatic neuroendocrine carcinomas (hgPNECs) represent about 5% of all PNENs. They show highly aggressive behavior with dismal prognosis. Throughout the last two decades, there has been a notable progress in basic and clinical research of PNENs and a therapeutic trend towards both more aggressive and minimally invasive surgery. Despite these advances, hgPNECs as a distinct clinical entity remains largely unexplored among surgeons. This review of current development in pathology reporting and surgical treatment of hgPNECs aims at increasing the awareness of an evolving field in pancreatic surgery.

Entities:  

Keywords:  Gastroenteropancreatic neuroendocrine tumor; Neuroendocrine carcinoma; Neuroendocrine neoplasm; Neuroendocrine tumor; Pancreas; Pancreatic cancer; Pancreatic neoplasm; Pancreatic surgery; Review

Mesh：

Substances：

Year:  2016        PMID： 26984415     DOI： 10.1007/s11912-016-0518-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  44 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

3.  A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram.

Authors:  Trevor A Ellison; Christopher L Wolfgang; Chanjuan Shi; John L Cameron; Peter Murakami; Liew Jun Mun; Aatur D Singhi; Toby C Cornish; Kelly Olino; Zina Meriden; Michael Choti; Luis A Diaz; Timothy M Pawlik; Richard D Schulick; Ralph H Hruban; Barish H Edil
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

4.  Discordance of Histologic Grade Between Primary and Metastatic Neuroendocrine Carcinomas.

Authors:  Taiwo Adesoye; Marie A Daleo; Agnes G Loeffler; Emily R Winslow; Sharon M Weber; Clifford S Cho
Journal:  Ann Surg Oncol       Date:  2015-07-21       Impact factor: 5.344

5.  Outcome after laparoscopic enucleation for non-functional neuroendocrine pancreatic tumours.

Authors:  Laureano Fernández-Cruz; Víctor Molina; Rodrigo Vallejos; Enrique Jiménez Chavarria; Miguel-Angel López-Boado; Joana Ferrer
Journal:  HPB (Oxford)       Date:  2012-01-09       Impact factor: 3.647

6.  Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.

Authors:  Xavier M Keutgen; Naris Nilubol; Joanne Glanville; Samira M Sadowski; David J Liewehr; David J Venzon; Seth M Steinberg; Electron Kebebew
Journal:  Surgery       Date:  2015-10-06       Impact factor: 3.982

7.  Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Authors:  Fritz-Line Vélayoudom-Céphise; Pierre Duvillard; Lydia Foucan; Julien Hadoux; Cecile N Chougnet; Sophie Leboulleux; David Malka; Joël Guigay; Diane Goere; Thierry Debaere; Caroline Caramella; Martin Schlumberger; David Planchard; Dominique Elias; Michel Ducreux; Jean-Yves Scoazec; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

8.  Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases.

Authors:  Stefano Partelli; Marco Inama; Anja Rinke; Nehara Begum; Roberto Valente; Volker Fendrich; Domenico Tamburrino; Tobias Keck; Martyn E Caplin; Detlef Bartsch; Christina Thirlwell; Giuseppe Fusai; Massimo Falconi
Journal:  Neuroendocrinology       Date:  2015-05-29       Impact factor: 4.914

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

Review 10.  Surgical treatment of sporadic pancreatic neuroendocrine tumors: a state of the art review.

Authors:  Sven-Petter Haugvik; Knut Jørgen Labori; Bjørn Edwin; Øystein Mathisen; Ivar Prydz Gladhaug
Journal:  ScientificWorldJournal       Date:  2012-12-10
View more
  2 in total

Review 1.  Pancreatic neuroendocrine tumors.

Authors:  Jian Sun
Journal:  Intractable Rare Dis Res       Date:  2017-02

Review 2.  Management of Large Cell Neuroendocrine Carcinoma.

Authors:  Virginia Corbett; Susanne Arnold; Lowell Anthony; Aman Chauhan
Journal:  Front Oncol       Date:  2021-08-27       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.